Sandbox c9
From Proteopedia
(Difference between revisions)
| Line 5: | Line 5: | ||
It was the first centrally-acting cholinesterase inhibitor approved for the treatment of Alzheimer's disease. | It was the first centrally-acting cholinesterase inhibitor approved for the treatment of Alzheimer's disease. | ||
| - | Tacrine’s ring is stacked between the aromatic rings of tryptophan 84 and phenylalanine 330 | + | Tacrine’s ring is stacked between the aromatic rings of tryptophan 84 and phenylalanine 330 |
Harel M, Schalk I, Ehret-Sabatier L, Bouet F, Goeldner M, Hirth C, Axelsen PH, Silman I, Sussman JL. Quaternary ligand binding | Harel M, Schalk I, Ehret-Sabatier L, Bouet F, Goeldner M, Hirth C, Axelsen PH, Silman I, Sussman JL. Quaternary ligand binding | ||
<Structure load='1ACJ' size='500' frame='true' align= LEFT' caption= ESTRUCTURA' /> | <Structure load='1ACJ' size='500' frame='true' align= LEFT' caption= ESTRUCTURA' /> | ||
| - | <scene name='Sandbox_c9/Inhibidor/3'> | + | <scene name='Sandbox_c9/Inhibidor/3'>(W84 and F330).</scene> |
Revision as of 13:07, 23 November 2010
1ACJ shows the crystal structure of Torpedo californica acetylcholinesterase (TcAChE) complexed with tacrine.
Tacrine is a parasympathomimetic and a centrally acting cholinesterase inhibitor.
It was the first centrally-acting cholinesterase inhibitor approved for the treatment of Alzheimer's disease.
Tacrine’s ring is stacked between the aromatic rings of tryptophan 84 and phenylalanine 330
Harel M, Schalk I, Ehret-Sabatier L, Bouet F, Goeldner M, Hirth C, Axelsen PH, Silman I, Sussman JL. Quaternary ligand binding
|
